Kanāda - angļu - Health Canada

jamp pharma corporation - finasteride - tablet - 5mg - finasteride 5mg - 5 alfa reductase inhibitors

Kanāda - angļu - Health Canada

mint pharmaceuticals inc - finasteride - tablet - 1mg - finasteride 1mg

Kanāda - angļu - Health Canada

mint pharmaceuticals inc - finasteride - tablet - 5mg - finasteride 5mg - 5 alfa reductase inhibitors

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride -

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride tablets usp are indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only. efficacy in bitemporal recession has not been established. finasteride tablets usp are not indicated for use in women. finasteride tablets usp are contraindicated in the following:  • pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. [see warnings and precautions (5.1), use in specific populations (8.1), how supplied/storage and handling (16) and patient counseling information (17.1).] in female rats, low doses of fina

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; docusate sodium; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide yellow; indigo carmine aluminium lake - aurobindo finasteride is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lauroyl macrogolglycerides; lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - finasteride gh 5 5 mg is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; lauroyl macrogolglycerides; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - finasteride gh 1 mg is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. finasteride gh 1 mg is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride tablets are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to:      -     improve symptoms      -    reduce the risk of acute urinary retention      -    reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride tablets administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of bph (a confirmed ≥ 4 point increase in american urological association (aua) symptom score). finasteride tablets are not approved for the prevention of prostate cancer.   finasteride tablets are contraindicated in the following: - hypersensitivity to any component of this medication. - pregnancy. finasteride use is contraindicated in females when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bryant ranch prepack - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride tablets are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to:      -     improve symptoms      -    reduce the risk of acute urinary retention      -    reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride tablets administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of bph (a confirmed ≥ 4 point increase in american urological association (aua) symptom score). finasteride tablets are not approved for the prevention of prostate cancer.   finasteride tablets are contraindicated in the following: - hypersensitivity to any component of this medication. - pregnancy. finasteride use is contraindicated in females when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride